Results 1 to 10 of about 30,350 (261)

The Current Status, Trend, and Development Strategies of Chinese Biopharmaceutical Industry With a Challenging Perspective

SAGE Open, 2020
Biopharmaceutical technology is one of the most promising biotechnologies in the world. With the development of modern biotechnology, biopharmaceuticals are thriving and developing rapidly as a global high-tech biotechnology industry, bringing the ...
Wuyi Liu, Wuyi Liu, Kerong Zhang
exaly   +2 more sources

Identification of Existing Gaps to Complete Technological Catch-up in the Iranian biopharmaceutical industry: A Comparative Study Approach [PDF]

بهبود مدیریت, 2022
Technological catch-up is a very complex and time-consuming process that requires all kinds of capabilities to be acquired by the latercomer firms in order to successfully complete the various stages.
Ahmad Jafarnejad Chaghooshi, Fatemeh Saghafi, Fatemeh Mojiri, Mohammad Amin Fakhimi   +3 more
doaj   +1 more source

Interferon-Based Biopharmaceuticals: Overview on the Production, Purification, and Formulation

Vaccines, 2021
The advent of biopharmaceuticals in modern medicine brought enormous benefits to the treatment of numerous human diseases and improved the well-being of many people worldwide.
Leonor S. Castro, Guilherme S. Lobo, Patrícia Pereira, Mara G. Freire, Márcia C. Neves, Augusto Q. Pedro   +5 more
doaj   +1 more source

Risk Factors of Supply Chain in Biopharmaceutical Companies in Iran [PDF]

Pharmaceutical Sciences, 2021
Background: Supply chain risk management can help companies detect potential hazards,mitigate potential risks, and thereby increase supply chain efficiency. The biopharmaceuticalindustry in Iran has a generic-based pharmerging market.
Hadi Abbasian, Reza Yousefi-Zenouz, Akbar Abdollahiasl, Mahdi Toroski, Shekoufeh Nikfar, Mohammadreza Siahi-Shadbad, Abbas Kebriaeezadeh   +6 more
doaj   +1 more source

Interlaboratory Studies Using the NISTmAb to Advance Biopharmaceutical Structural Analytics

Frontiers in Molecular Biosciences, 2022
Biopharmaceuticals such as monoclonal antibodies are required to be rigorously characterized using a wide range of analytical methods. Various material properties must be characterized and well controlled to assure that clinically relevant features and ...
Katharina Yandrofski, Trina Mouchahoir, M. Lorna De Leoz, David Duewer, Jeffrey W. Hudgens, Kyle W. Anderson, Luke Arbogast, Frank Delaglio, Robert G. Brinson, John P. Marino, Karen Phinney, Michael Tarlov, John E. Schiel   +12 more
doaj   +1 more source

Cell-free protein synthesis: advances on production process for biopharmaceuticals and immunobiological products

BioTechniques, 2021
Biopharmaceutical products are of great importance in the treatment or prevention of many diseases and represent a growing share of the global pharmaceutical market.
Camila Hiromi Chiba, Marcos Camargo Knirsch, Adriano Rodrigues Azzoni, Antonio R Moreira, Marco Antonio Stephano   +4 more
doaj   +1 more source

Immunogenicity of biopharmaceuticals [PDF]

Nephrology Dialysis Transplantation, 2006
The availability of biopharmaceuticals has been increasing over the past decade and as their patents expire, the emergence of biosimilar agents approaches. The primary issue of concern for the safety of these agents is the potential for immunogenicity.
Michele, Kessler, David, Goldsmith, Huub, Schellekens   +2 more
openaire   +2 more sources

Comparing the odds of reported depression in psoriasis patients on systemic therapy: a cross-sectional analysis of postmarketing data

Journal of Dermatological Treatment, 2023
Patients with psoriasis are more likely to experience depression and suicidality compared to non-psoriatic patients, though systemic therapies have been shown to improve depressive symptoms.
Samuel Yeroushalmi, Mimi Chung, Erin Bartholomew, Marwa Hakimi, John Koo   +4 more
doaj   +1 more source

Glyco-Engineering Plants to Produce Helminth Glycoproteins as Prospective Biopharmaceuticals: Recent Advances, Challenges and Future Prospects

Frontiers in Plant Science, 2022
Glycoproteins are the dominant category among approved biopharmaceuticals, indicating their importance as therapeutic proteins. Glycoproteins are decorated with carbohydrate structures (or glycans) in a process called glycosylation.
Alex van der Kaaij, Kim van Noort, Pieter Nibbering, Ruud H. P. Wilbers, Arjen Schots   +4 more
doaj   +1 more source

The biopharmaceutical anomaly [PDF]

Nature Biotechnology, 2020
Investment and funding has continued to flow into biotech, unlike most business sectors. But with healthcare and hospital budgets increasingly under pressure, do belt-tightening and consolidation lie ahead? Melanie Senior investigates, with additional reporting by Riku Lahteenmaki.
openaire   +2 more sources